Why Is MapLight Therapeutics (MPLT) Stock Down -67% Today?
Key Takeaways
- MapLight Therapeutics shares plunged approximately 67% on Monday, hitting a new 52-week low after the company reported mixed topline results from its pivotal Phase 2 ZEPHYR trial.
- The primary catalyst: While the twice-daily (BID) dose of schizophrenia candidate ML-007C-MA met its primary endpoint, the once-daily (QD) dosing regimen failed to achieve statistical significance, disappointing investors who had priced in a best-case scenario.
- Secondary drivers: The PANSS improvement of 4.5 points versus placebo, though statistically significant, was viewed by some market participants as underwhelming when compared against the established efficacy bar set by Bristol Myers Squibb's Cobenfy.
- The stock had rallied 108% year-to-date ahead of the data readout, leaving it vulnerable to a sharp selloff on any outcome short of unequivocal success across both dosing arms.
- Most Wall Street analysts maintained bullish ratings despite the selloff, though Raymond James cut its price target, citing reduced peak sales estimates.
- Traders are now watching the company's planned End-of-Phase 2 meeting with the FDA and a confirmatory Phase 3 trial design, as well as additional data expected later in 2026.
Opening Summary
MPLT, the stock of MapLight Therapeutics, Inc.—a clinical-stage biopharmaceutical company focused on developing novel therapies for central nervous system disorders including schizophrenia, Alzheimer's disease psychosis, and autism spectrum disorder—collapsed roughly 67% in Monday's trading session. The shares, which closed at $36.56 on Friday, July 24, were trading near $12.03 intraday, wiping out more than two-thirds of the company's market value in a single session. The selloff was triggered by the release of mixed Phase 2 ZEPHYR trial results for the company's lead drug candidate, ML-007C-MA, an oral muscarinic therapy for schizophrenia. While the twice-daily dose met the trial's primary endpoint with statistical significance, the once-daily arm missed, shattering investor expectations for a clean sweep.
Phase 2 ZEPHYR Trial: A Mixed Verdict
The ZEPHYR trial enrolled 307 patients across 25 U.S. sites, randomizing participants to receive either a 210/3 mg twice-daily (BID) dose of ML-007C-MA, a 330/6 mg once-daily (QD) dose, or placebo. At the Week 5 primary endpoint, the BID arm delivered a placebo-adjusted PANSS improvement of 4.5 points—an effect size of 0.37 that cleared the bar for statistical significance (p=0.015). The BID regimen also achieved significance on key secondary endpoints, including Clinical Global Impression of Severity (CGI-S), PANSS positive symptoms, and a cognition composite score, with cognitive benefits appearing independent of psychotic symptom relief.
However, the once-daily arm—widely seen as a crucial competitive differentiator against Bristol Myers Squibb's BMY Cobenfy—failed to reach statistical significance on the primary endpoint, posting a placebo-adjusted PANSS improvement of just 2.8 points (p=0.11). This miss was the core of Monday's rout. Investors had banked on ML-007C-MA's once-daily convenience as a commercial advantage, and the ambiguous outcome cast a shadow over the drug's market positioning and peak sales potential.
Efficacy Perception Versus Market Expectations
Beyond the binary pass/fail narrative, investors also appeared to scrutinize the magnitude of the BID arm's efficacy. The 4.5-point PANSS improvement versus placebo, while statistically significant, fell short of the effect sizes generated by Cobenfy in its pivotal trials. Analysts noted that market participants may compare the data unfavorably, despite the fact that Cobenfy's real-world tolerability has proven more challenging than its clinical trial profile suggested. On the tolerability front, ML-007C-MA showed a relatively benign profile—nausea occurred in 29% of patients and vomiting in 13%, figures meaningfully lower than Cobenfy's real-world rates. Yet on a day when fear dominated, these nuances were largely swept aside.
Market Context and Trading Activity
Monday's volume in MPLT shares soared to well over 1.7 million shares within hours of the open, dwarfing the stock's 10-day average volume of approximately 620,000 shares. The stock sliced through its 50-day moving average of $32.17 and its 200-day moving average of $25.08 without pause, ultimately touching a 52-week low of $11.27 before stabilizing near the $12 level. The carnage was isolated to MapLight rather than reflecting broader biotech weakness; the SPDR S&P Biotech ETF (XBI) traded relatively flat, underscoring that this was a stock-specific event driven purely by clinical data.
The selloff was amplified by the stock's prior run-up. MapLight had gained 108% year-to-date and roughly 99% over the trailing twelve months heading into the readout, reflecting lofty expectations baked into the share price. When the data failed to deliver across both dosing arms, the air came out rapidly.
What Comes Next for MPLT
MapLight Therapeutics now plans to request an End-of-Phase 2 meeting with the U.S. Food and Drug Administration to align on the design of a confirmatory Phase 3 trial for ML-007C-MA in schizophrenia. The company is conducting additional exposure analyses to determine whether a once-daily regimen can be salvaged through dose optimization. Separately, MapLight continues to advance its VISTA Phase 2 trial evaluating ML-007C-MA in Alzheimer's disease psychosis, with topline data expected in the second half of 2027.
Analysts remain broadly constructive despite the selloff. Jefferies, BMO Capital, Stifel, and Canaccord all reiterated Buy-equivalent ratings, while Raymond James trimmed its target to $35 from $46. The consensus analyst target sits around $40.82, implying significant upside from current levels. Still, risks remain considerable: the company must now demonstrate that it can design and execute a Phase 3 program that satisfies the FDA, and the once-daily miss introduces uncertainty around the drug's ultimate commercial profile—and therefore its peak revenue opportunity.
Trending AI Robots
For investors seeking data-driven insights in volatile markets like biotech, Tickeron's Trending AI Robots page highlights a curated selection of AI-powered trading bots that have demonstrated strength under current market conditions. With hundreds of bots covering thousands of tickers and spanning diverse strategies, timeframes, and performance metrics, only the top performers make the cut. Whether you trade momentum, value, or technical patterns, exploring the Trending AI Robots can help you identify systematic approaches aligned with today's market dynamics.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.
MPLT's RSI Oscillator dives into oversold zone
The RSI Indicator for MPLT moved into overbought territory on September 18, 2026. Be on the watch for a price drop or consolidation in the future -- when this happens, think about selling the stock or exploring put options.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
The Moving Average Convergence Divergence (MACD) for MPLT just turned positive on August 17, 2026. Looking at past instances where MPLT's MACD turned positive, the stock continued to rise in 5 of 5 cases over the following month. The odds of a continued upward trend are 90%.
Following a +6.16% 3-day Advance, the price is estimated to grow further. Considering data from situations where MPLT advanced for three days, in 38 of 44 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
MPLT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on September 15, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on MPLT as a result. In 18 of 21 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 86%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MPLT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 16 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.454) is normal, around the industry mean (25.929). P/E Ratio (0.000) is within average values for comparable stocks, (40.079). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.178). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (437.043).
The Tickeron Price Growth Rating for this company is 85 (best 1 - 100 worst), indicating slightly worse than average price growth. MPLT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MPLT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement